戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ulture infections model and in vivo model of bacterial keratitis.
2 ids to topical moxifloxacin hydrochloride in bacterial keratitis.
3 models, the present study tested its role in bacterial keratitis.
4 ical corticosteroid treatment on outcomes in bacterial keratitis.
5 mediated corneal damage resulting from acute bacterial keratitis.
6  or an epithelial plaque was associated with bacterial keratitis.
7 expression and activation after induction of bacterial keratitis.
8  present with an increased susceptibility to bacterial keratitis.
9 ple method for the investigation of presumed bacterial keratitis.
10  evaluated for virulence in a mouse model of bacterial keratitis.
11 ungal keratitis, and contact lens-associated bacterial keratitis.
12 otic may be appropriate for certain cases of bacterial keratitis.
13 e for identifying pathogens in patients with bacterial keratitis.
14 L) have the potential to improve outcomes in bacterial keratitis.
15  non-invasive treatment option for resistant bacterial keratitis.
16 o topical antibiotics alone for treatment of bacterial keratitis.
17 ble in the developing world for treatment of bacterial keratitis.
18                          Of 95 patients with bacterial keratitis, 103 patients with fungal keratitis,
19              Of a total of 224 patients with bacterial keratitis, 114 patients were randomized to gro
20 cords of 115 patients with laboratory-proven bacterial keratitis, 115 patients with laboratory-proven
21              Thirty-eight out of 44 cases of bacterial keratitis (86.36%) were diagnosed by solid med
22                                           In bacterial keratitis, a higher MIC to the treating antibi
23 e of therapeutic value for the management of bacterial keratitis, a prevalent cause of vision loss an
24 n was recovered in 977 samples (57.4%), with bacterial keratitis accounting for 897 of the positive c
25 ium phosphate to placebo in the treatment of bacterial keratitis among 500 patients with culture-posi
26 ections and is commonly isolated in cases of bacterial keratitis, an infection of the cornea.
27  till the complete healing and resolution of bacterial keratitis and confirmation by negative bacteri
28 diagnose IK (model 1), differentiate between bacterial keratitis and fungal keratitis (model 2), and
29 TOR regulates IL-10 in P. aeruginosa-induced bacterial keratitis and is critical to balancing pro- an
30 al antibiotics remain the best treatment for bacterial keratitis, and a recent review found all commo
31  causative organisms and clinical outcome in bacterial keratitis, and is likely on the causal pathway
32 confidence in making the proper diagnosis of bacterial keratitis, and the level of trust in the antib
33 valuated the role of adjuvant corneal CXL in bacterial keratitis, and the other study focused mainly
34  method) is as reliable for the diagnosis of bacterial keratitis as inoculation of multiple scrapes d
35 entous fungal keratitis and 24 patients with bacterial keratitis (as controls).
36 reatment effectively alleviated experimental bacterial keratitis, as evidenced by substantial reducti
37                                              Bacterial keratitis (BK) is a major cause of corneal bli
38                                              Bacterial keratitis (BK) is an ocular disorder associate
39 sorption (WA) for the treatment of resistant bacterial keratitis (BK).
40 early identification of potential fungal and bacterial keratitis cases and helps enable timely manage
41            Microbiology records of suspected bacterial keratitis cases that underwent a diagnostic co
42 ulation with a previous episode of fungal or bacterial keratitis, correctable bilateral visual impair
43 uginosa is a common organism associated with bacterial keratitis, especially in extended-wear contact
44 ed of 100 of 152 individuals whose fungal or bacterial keratitis had been diagnosed 4 years prior and
45 on with topical antibiotics for treatment of bacterial keratitis in areas of the world where use of e
46      This is the first report of spontaneous bacterial keratitis in mice.
47 ponse propensity affects the pathogenesis of bacterial keratitis in mice.
48 e shows delayed healing and poor clearing of bacterial keratitis; in vitro its epithelial protein ext
49           CD36(-/-) mice develop spontaneous bacterial keratitis independent of TLR2 and TSP1.
50                                              Bacterial keratitis is a sight-threatening infection of
51 y Pseudomonas aeruginosa, a leading cause of bacterial keratitis, is facilitated by the bacterial Psl
52 ancomycin in the setting of severe suspected bacterial keratitis may be justified.
53 ions, its efficacy was evaluated in a murine bacterial keratitis model.
54 rabbit model of soft contact lens-associated bacterial keratitis more often than its collagen-binding
55 ransient conjunctival hyperemia (n = 1), and bacterial keratitis (n = 1) which resolved with fortifie
56                                       Ocular bacterial keratitis, often associated with Pseudomonas a
57 ghty photographs of eyes with culture-proven bacterial keratitis or smear-proven fungal keratitis wer
58 l procedures and postoperative occurrence of bacterial keratitis, orbital infection, endophthalmitis,
59                             Nine (82%) of 11 bacterial keratitis patients were PCR positive; each seq
60                                Scarring from bacterial keratitis remains a leading cause of visual lo
61 identification of pathogens in patients with bacterial keratitis remains problematic because standard
62  with clinically suspected and lab-confirmed bacterial keratitis, resistant to appropriate antibiotic
63 ore effective for the treatment of resistant bacterial keratitis till complete epithelialization and
64           We randomized 172 individuals with bacterial keratitis to topical treatment with povidone-i
65 tion of the causative organisms in suspected bacterial keratitis traditionally involves collecting mu
66                                 All cases of bacterial keratitis treated at the University of Illinoi
67 roved post-surgical infection prevention and bacterial keratitis treatment outcomes.
68  causative organisms and clinical outcome in bacterial keratitis using data collected in a randomized
69 al infections of the eye can lead to corneal bacterial keratitis, visual impairment, and blindness.
70                 The rate of culture-positive bacterial keratitis was 0.022 infections per eye-year, a
71 a well-characterized in vivo rabbit model of bacterial keratitis was selected to study its contributi
72 ith prior fungal keratitis and 50 with prior bacterial keratitis were enrolled.
73                      Patients with suspected bacterial keratitis were identified from microbiological
74 rneal densitometry readings in subjects with bacterial keratitis were recorded during the active stag
75                     Recurrence and secondary bacterial keratitis were seen in 28 (14.5%) and 20 (10%)
76 thy controls and 36 eyes of 35 patients with bacterial keratitis were studied.
77 xpensive, can be considered for treatment of bacterial keratitis when antibiotic treatment is not pra
78 irst study to explore the role of miR-155 in bacterial keratitis, which may provide a promising targe
79 en patients had microbiologically documented bacterial keratitis, while 17 patients had keratitis due
80 o included were participants with concurrent bacterial keratitis who were using topical steroids and
81  of a simpler diagnostic method in suspected bacterial keratitis would be useful.